Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 14, Issue 3, 2012, Pages

  Farley, Joel F ^a   Hansen, Richard A ^b   Yu Isenberg, Kristina S ^c   Maciejewski, Matthew L ^d  

^a University of North Carolina   (United States)

^b AUBURN UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; CLOZAPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; ATTITUDE TO HEALTH; CHRONIC DISEASE; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG COST; FEMALE; HEALTH BELIEF; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POPULATION RESEARCH; PREDICTION; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT DURATION;

EID: 84864650435     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.11m01324     Document Type: Article

References (14)

1. Correll CU, Druss BG, Lombardo I, et al. Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv. 2010;61(9):892-898. PubMed
2. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1-3):15-22. PubMed doi:10.1016/j.schres.2006.06.026 Show Abstract Show Abstract
3. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115-1121. PubMed doi:10.1016/j.ahj.2005.02.007 Show Abstract Show Abstract
4. Morrato EH, Newcomer JW, Kamat S, et al. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care. 2009;32(6):1037-1042. PubMed doi:10.2337/dc08-1720 Show Abstract Show Abstract
5. Mann JJ. The medical management of depression. N Engl J Med. 2005;353(17):1819-1834. PubMed doi:10.1056/NEJMra050730 Show Abstract Show Abstract
6. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255-264. PubMed doi:10.1093/oxfordjournals.schbul.a007076 Show Abstract Show Abstract
7. Lurie N, Popkin M, Dysken M, et al. Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp Community Psychiatry. 1992;43(1):69-71. PubMed Show Abstract Show Abstract
8. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. PubMed doi:10.1001/jama.288.4.455 Show Abstract Show Abstract
9. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303-2310. PubMed doi:10.1185/03007990903126833 Show Abstract Show Abstract
10. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. PubMed doi:10.1097/01.mlr.0000182534.19832.83 Show Abstract Show Abstract
11. Dombrovski A, Rosenstock J. Bridging general medicine and psychiatry: providing general medical and preventative care for the severely mentally ill. Curr Opin Psychiatry. 2004;17(6):523-529. doi:10.1097/00001504-200411000-00018
12. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry. 1999;60(suppl 21):10-15. PubMed Show Abstract Show Abstract
13. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. PubMed doi:10.1056/NEJMoa051688 Show Abstract Show Abstract
14. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. PubMed doi:10.1093/aje/kwg231 Show Abstract Show Abstract